ResearcherJilin UniversityNo recent work listed
Guan Wang
Matched on ORCID iD 0000-0003-1407-5778; OpenAlex author ID A5101403245.
Their work
- Papers
- 7 (first author 3, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 7
2012: 1 paper · 2013: none · 2014: 2 papers · 2015: 1 paper · 2016: none · 2017: 2 papers · 2018: none · 2019: none · 2020: none · 2021: 1 paper
Papers 7
- Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer. Last author DOI 10.1007/s00280-020-04210-0↗
- Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer. Co-author DOI 10.18632/oncotarget.17869↗
- Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA damage and abrogation of ribonucleotide… Last author DOI 10.3892/or.2017.5580↗
- Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer. First author DOI 10.1016/j.canlet.2014.10.015↗
- Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2014.02.010↗
- Combination of chloroquine and GX15-070 (obatoclax) results in synergistic cytotoxicity against pancreatic cancer cells. First author DOI 10.3892/or.2014.3525↗
- Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer. First author DOI 10.1371/journal.pone.0052095↗
Closest collaborators
The 7 strongest of 7 ranked by shared papers, trials and grants, with recent and small-team work weighing most.
- Yubin Ge · 6 shared papers, 2012–2017
- Paper Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA… DOI 10.3892/or.2017.5580↗
- Paper Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of … DOI 10.18632/oncotarget.17869↗
- Paper Combination of chloroquine and GX15-070 (obatoclax) results in synergistic cytotoxicity against pancreatic cancer cells. DOI 10.3892/or.2014.3525↗
- Shuang Liu · 3 shared papers, 2017–2021
- Paper Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer. DOI 10.1007/s00280-020-04210-0↗
- Paper Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA… DOI 10.3892/or.2017.5580↗
- Paper Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of … DOI 10.18632/oncotarget.17869↗
- Shaohua Chen · 2 shared papers, 2014
- Paper Combination of chloroquine and GX15-070 (obatoclax) results in synergistic cytotoxicity against pancreatic cancer cells. DOI 10.3892/or.2014.3525↗
- Paper Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical m… DOI 10.1016/j.canlet.2014.02.010↗
- Asfar Sohail Azmi · 2 shared papers, 2012–2017
- Paper Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of … DOI 10.18632/oncotarget.17869↗
- Paper Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer. DOI 10.1371/journal.pone.0052095↗
- Tingting Wang · 1 shared paper, 2017
- Changwen Ning · 1 shared paper, 2017
- Yingjie Guo · 1 shared paper, 2012
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.